Biotech News

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

TG Therapeutics (TGTX)TG Therapeutics2026-06-25 13:46 ESTClinical readout

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safety and tolerability of the consolidated first infusion were consistent with the established BRIUMVI

Open original release

Related news

TGTXTG Therapeutics2026-06-25 13:46 EST

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TGTXTG Therapeutics2026-06-25 13:46 EST

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TGTXTG Therapeutics2026-06-25 13:46 EST

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

TGTXTG Therapeutics2026-06-25 13:46 EST

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

TGTXTG Therapeutics2026-06-25 13:46 EST

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

TGTXTG Therapeutics2026-06-25 13:46 EST

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TGTXTG Therapeutics2026-06-25 13:46 EST

Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

TGTXTG Therapeutics2026-06-25 13:46 EST

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

TGTXTG Therapeutics2026-06-25 13:46 EST

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

TGTXTG Therapeutics2026-06-25 13:46 EST

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

View all latest news

TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

TGTXTG Therapeutics2026-06-26 09:48 EST

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TGTXTG Therapeutics2026-06-26 09:48 EST

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

TGTXTG Therapeutics2026-06-26 09:48 EST

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

TGTXTG Therapeutics2026-06-26 09:48 EST

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

TGTXTG Therapeutics2026-06-26 09:48 EST

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States